CASTLEClopidogrel 600 mg and 300 mg as a Loading Dose Prior to Percutaneous Coronary Intervention And Serum Troponin Level Elevation: A Pilot Study

Fecha de inicio: 1 de mayo de 2004

Inclusion Criteria: * Patients having symptomatic coronary artery disease with objective evidence of ischemia (eg, symptoms of angina pectoris, positive stress test results or dynamic electrocardiographic (ECG) changes). * Patients undergoing stent implantation Exclusion Criteria: * Any known contraindication to the use of aspirin or clopidogrel. * Patients receiving clopidogrel within 10 days, thrombolytics within 24 hours or receiving oral anticoagulation therapy * Elective administration of IIb/IIIa inhibitors. * Cardiogenic shock * Acute MI\< 24 hours * BP systolic \<100 mmHg * Left ventricular ejection fraction \< 30% * Heart failure, NYHA class III or IV * Severe renal insufficiency (creatinine \> 3.0 mg/dL) * Platelet count \<100,000/mm³ * Target lesion in a venous bypass graft * Target lesion in a chronic occlusion The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.